London, England United Kingdom (PressExposure) November 25, 2011 -- The effectiveness of new drugs against disorders affecting the central nervous system is greatly dependent on the use of rating scales in randomized clinical trials. Some of the ratings scales used in clinical trials for drugs targeting CNS disorders include the Brief Psychiatric Rating Scale (BPRS), Positive and Negative Syndrome Scale (PANSS), the Hamilton Depression and Anxiety Scales (HAM-D and HAM-A), the Mini-Mental State Examination (MMSE). These scales have been widely used in disorders such as Depression, Epilepsy, Alzheimers and Schizophrenia. Although these measures are subjective, their use stems from the fact that they provide a sufficiently high degree of reliability and validity on trait performance.
For Sample Pages, please click or add the below link to your browser: http://gbiresearch.com/RequestSamplePages.aspx?ID=Endpoints-Clinical-Trials-in-CNS-Disorders-Multiple-Endpoints-and-Ratings-Scales-are-Becoming-More-Widely-Adopted&Title=Pharmaceuticals_and_Healthcare&ReportType=Industry_Report&CompanyID=pexpo
GBI Research, the leading business intelligence provider, has released its latest research "Endpoints - Clinical Trials in CNS Disorders - Multiple Endpoints and Ratings Scales are Becoming More Widely Adopted" which provides an insight into different endpoints used for the central nervous system in clinical trials. The report examines different aspects under clinical trial endpoints in central nervous system disorders such as analysis on major marketed Central nervous system drugs with an emphasis on safety and efficacy details, Phase II and Phase III clinical trial analysis for both completed and ongoing clinical trials, most promising Central nervous system drugs with details on safety, efficacy and clinical trials, and terminated trial analysis. The company profiling highlights the central nervous system drugs of different companies.
The global CNS disease market is valued as $53.1 billion in 2010 that grew from $36.8 billion in 2002 with a CAGR of 4.7%. An increase in geriatric population in many countries combined with increased life expectancy is expected to increase disease population of CNS disease. The product pipeline of CNS disease is promising with many novel molecules with disease modifying characteristics at various stages of development, which are expected to fulfill the unmet needs in the CNS disease market. The product pipeline for the multiple sclerosis has many orally administered novel molecules whereas for alzheimer's disease, the product pipeline have novel molecules such as Bapineuzumab, Solanezumab, BMS-708163 which target the underlying causes of the disease and thus may offer significant benefits to the patients. The market for Schizophrenia and bipolar disorder is estimated to be driven by the anticipated launch of AZ-004 and other molecules such as Cariprazine, Zicronapine, RG1678 and Aripiprazole Depot injection. The continued uptake of non stimulants and expected launch of Kapvay and other pipeline molecules will have significant impact on market for ADHD. Although in upcoming years market will witness the patent expiries of major drugs, however rapid uptake of new molecules will stabilize the market decline and the market is expected to grow with a CAGR of 1.4% from 2010 to 2017 to reach $58.6 billion in 2017.
This report details "Endpoints - Clinical Trials in Central nervous system Disorders", highlighting the five major central nervous system disorders which are Alzheimer's disease, Depression, Epilepsy, Parkinson's disease and Schizophrenia. The classification of five major central nervous system diseases is done on the basis of, the number of pipeline molecules present in Phase III stage of development.
The term endpoint refers to an outcome or measure of a clinical trial. Endpoints can include all kinds of aspects, those related to the effectiveness of treatment and others. However, the endpoint selection must take into account the need to obtain the highest information of therapeutic interest with the least risk and discomfort for the individual. Also, the endpoints must be to the objective of the study and represent the most effective way to assess pharmacological response.
For further details, please click or add the below link to your browser:
Visit our report store: http://www.gbiresearch.com
For more details contact:
North America: +1 646 395 5477
Europe: +44 207 753 4299
+44 1204 543 533
Asia Pacific: +91 40 6616 6782